TARCEVA Drug Patent Profile
✉ Email this page to a colleague
When do Tarceva patents expire, and what generic alternatives are available?
Tarceva is a drug marketed by Osi Pharms and is included in one NDA.
The generic ingredient in TARCEVA is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tarceva
A generic version of TARCEVA was approved as erlotinib hydrochloride by RISING on June 11th, 2014.
Summary for TARCEVA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 240 |
| Clinical Trials: | 428 |
| Patent Applications: | 4,270 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TARCEVA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TARCEVA |
| What excipients (inactive ingredients) are in TARCEVA? | TARCEVA excipients list |
| DailyMed Link: | TARCEVA at DailyMed |
Recent Clinical Trials for TARCEVA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hala Fadda | Phase 1 |
| Butler University | Phase 1 |
| Indiana University | Phase 1 |
Pharmacology for TARCEVA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TARCEVA
Paragraph IV (Patent) Challenges for TARCEVA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TARCEVA | Tablets | erlotinib hydrochloride | 25 mg | 021743 | 1 | 2008-11-18 |
US Patents and Regulatory Information for TARCEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-003 | Nov 18, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARCEVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-003 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-001 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| Osi Pharms | TARCEVA | erlotinib hydrochloride | TABLET;ORAL | 021743-002 | Nov 18, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TARCEVA
See the table below for patents covering TARCEVA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Norway | 2006004 | ⤷ Try a Trial | |
| Israel | 129994 | ALKOXY-SUBSTITUTED 4-CHLOROQUINAZOLINES | ⤷ Try a Trial |
| African Intellectual Property Organization (OAPI) | 10277 | Quinazoline derivatives | ⤷ Try a Trial |
| European Patent Office | 0817775 | DERIVES DE QUINAZOLINE (QUINAZOLINE DERIVATIVES) | ⤷ Try a Trial |
| Bulgaria | 106761 | ⤷ Try a Trial | |
| Norway | 20021910 | ⤷ Try a Trial | |
| Japan | 4689916 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARCEVA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0817775 | 300214 | Netherlands | ⤷ Try a Trial | 300214, 20150606, EXPIRES: 20200320 |
| 0817775 | C00817775/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
| 0817775 | CA 2006 00006 | Denmark | ⤷ Try a Trial | |
| 0817775 | 5/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321 |
| 0817775 | 91209 | Luxembourg | ⤷ Try a Trial | 91209, EXPIRES: 20200321 |
| 0817775 | SPC001/2006 | Ireland | ⤷ Try a Trial | SPC001/2006: 20070817, EXPIRES: 20200320 |
| 0817775 | 06C0010 | France | ⤷ Try a Trial | PRODUCT NAME: ERLOTINIB HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 20050919; FIRST REGISTRATION: LI - 57266 20050321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
